Hepatitis B virus variants

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 8, 2009, Pages 453-462

  Chotiyaputta, Watcharasak ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MULTIDRUG RESISTANCE; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VIRAL GENETICS; VIREMIA; VIRUS CORE; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 68549087141     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.107     Document Type: Review

References (99)

1. Summers, J. & Mason, W. S. replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29, 403-415 (1982).
2. Nowak, M. A. et al. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93, 4398-4402 (1996).
3. Girones, R. & Miller, R. H. Mutation rate of the hepadnavirus genome. Virology 170, 595-597 (1989).
4. Locarnini, S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin. Liver Dis. 25 (Suppl. 1), 9-19 (2005).
5. Zhang, Y. Y. & Summers, J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J. Virol. 73, 3616-3622 (1999).
6. Roossinck, M. J., Jameel, S., Loukin, S. H. & Siddiqui, A. Expression of hepatitis B viral core region in mammalian cells. Mol. Cell Biol. 6, 1393-1400 (1986).
7. Ou, J. H., Laub, O. & Rutter, W. J. Hepatitis B virus gene function: The precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl Acad. Sci. USA 83 1578-1582 (1986).
8. Milich, D. R. et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl Acad. Sci. USA 87, 6599-6603 (1990).
9. Carman, W. F. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2, 588-591 (1989).
10. Kramvis, A. et al. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J. Med. Virol. 80, 27-46 (2008).
11. Lok, A. S., Akarca, U. & Greene, S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc. Natl Acad. Sci. USA 91, 4077-4081 (1994).
12. -mutant: Possible contribution of a single nucleotide in the precore region. J. Virol. 67, 5402-5410 (1993).
13. Chu, C. J. et al. Hepatitis B virus genotypes in the United states: Results of a nationwide study. Gastroenterology 125, 444-451 (2003).
14. Chu, C. J. et al. Prevalence of HBV precore/core promoter variants in the United states. Hepatology 38, 619-628 (2003).
15. Milich, D. & Liang, T. J. exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38, 1075-1086 (2003).
16. Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst. 100, 1134-1143 (2008).
17. Gunther, S., Piwon, N. & Will, H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with 1653C>T, 1762A>T and 1764G>A mutations in the core promoter. J. Gen. Virol. 79 (Pt 2), 375-380 (1998).
18. Parekh, S. et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J. Virol. 77, 6601-6612 (2003).
19. Buckwold, V. E., Xu, Z., Chen, M., Yen, T. S. & Ou, J. H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845-5851 (1996).
20. Chan, H. L., Hussain, M. & Lok, A. S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 29, 976-984 (1999).
21. Yuen, M. F. et al. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J. Viral Hepat. 12, 513-518 (2005).
22. Lin, C. L. et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 25, 564-570 (2005).
23. Sato, S. et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann. Intern. Med. 122, 241-248 (1995).
24. Yuen, M. F. et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: A case-control study. Carcinogenesis 25, 1593-1598 (2004).
25. Kao, J. H., Chen, P. J., Lai, M. Y. & Chen, D. S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124, 327-334 (2003).
26. Baptista, M., Kramvis, A. & Kew, M. C. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29, 946-953 (1999).
27. Funk, M. L., Rosenberg, D. M. & Lok, A. S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 9, 52-61 (2002).
28. Zarski, J. P. et al. Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. J. Hepatol. 45, 355-360 (2006).
29. Gaeta, G. B. et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J. Hepatol. 39, 1036-1041 (2003).
30. Hadziyannis, S. J. & Papatheodoridis, G. V. Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment. Semin. Liver Dis. 26, 130-141 (2006).
31. Chan, H. L., Leung, N. W., Hussain, M., Wong, M. L. & Lok, A. S. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 31, 763-768 (2000).
32. Manesis, E. K. HBeAg-negative chronic hepatitis B: From obscurity to prominence. J. Hepatol. 45, 343-346 (2006).
33. Brunetto, M. R. et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105, 845-850 (1993).
34. Lok, A. S., Akarca, U. S. & Greene, S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 21, 19-24 (1995).
35. Chu, C. M., Yeh, C. T., Lee, C. S., Sheen, I. S. & Liaw, Y. F. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J. Clin. Microbiol. 40, 16-21 (2002).
36. Chen, R. Y. et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37, 27-35 (2003).
37. Wu, I. C. et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin. Infect. Dis. 47, 1305-1311 (2008).
38. Lok, A. S. et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46, 254-265 (2007).
39. Allen, M. I. et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27, 1670-1677 (1998).
40. Seigneres, B. et al. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36, 710-722 (2002).
41. Colonno, R. J. et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44, 1656-1665 (2006).
42. Yuen, M. F. et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34, 785-791 (2001).
43. Yuen, M. F. et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46, 1695-1703 (2007).
44. Locarnini, S. et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J. Hepatol. 42, 17 (2005).
45. Liaw, Y. F. et al. 2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495 (2009).
46. Keeffe, E. B. et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5, 890-897 (2007).
47. Pawlotsky, J. M. et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology 134, 405-415 (2008).
48. Westland, C. E. et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38, 96-103 (2003).
49. Lai, C. L. et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687-696 (2003).
50. Lok, A. S. et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722 (2003).
51. Dienstag, J. L. et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124, 105-117 (2003).
52. Kim, H. S. et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antiviral Ther. 10, 441-449 (2005).
53. Hussain, M. et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44, 1094-1097 (2006).
54. Degertekin, B., Hussain, M., Tan, J., Oberhelman, K. & Lok, A. S. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 50, 42-48 (2009).
55. Hirsch, M. S. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS Society USA panel. Clin. Infect. Dis. 47, 266-285 (2008).
56. Solmone, M. et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83, 1718-1726 (2009).
57. Lee, C. H. et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 130 1144-1152 (2006).
58. Ono, S. K. et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107, 449-455 (2001).
59. Delaney, W. E. 4th et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77, 11833-11841 (2003).
60. Angus, P. et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125, 292-297 (2003).
61. Villeneuve, J. P. et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39, 1085-1089 (2003).
62. Zoulim, F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 64, 1-15 (2004).
63. Hadziyannis, S. J. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
64. Marcellin, P. et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48, 750-758 (2008).
65. Yeon, J. E. et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55, 1488-1495 (2006).
66. Lampertico, P. et al. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133, 1445-1451 (2007).
67. Schildgen, O. et al. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 354, 1807-1812 (2006).
68. Curtis, M., Zhu, Y. & Borroto-Esoda, K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J. Infect. Dis. 196, 1483-1486 (2007).
69. Carrouee-Durantel, S. et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antiviral Ther. 13, 381-388 (2008).
70. Tenney, D. J. et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48, 3498-3507 (2004).
71. Tenny, D. J. et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol. Int. 2, S213-S214 (2008).
72. Marcellin, P. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442-2455 (2008).
73. Snow-Lampart, A. et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd [Abstract]. Hepatology 48, 745A (2008).
74. Sheldon, J. et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antiviral Ther. 10, 727-734 (2005).
75. Delaney, W. E. 4th et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 50, 2471-2477 (2006).
76. Amini-Bavil-Olyaee, S. et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 49, 1158-1165 (2009).
77. Villet, S., Pichoud, C., Villeneuve, J. P., Trepo, C. & Zoulim, F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131, 1253-1261 (2006).
78. Yim, H. J. et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44, 703-712 (2006).
79. Lau, G. K. et al. Peginterferon α2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005).
80. Marcellin, P. et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004).
81. Sung, J. J. et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 48, 728-735 (2008).
82. Marcellin, P. et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 48, 370A-371A (2008).
83. Heathcote, E. J. et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis [Abstract]. Hepatology 48, 376A (2008).
84. Lampertico, P. et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42, 1414-1419 (2005).
85. Tan, J. et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 48, 391-398 (2008).
86. Torresi, J. et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293, 305-313 (2002).
87. * mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48, 88-98 (2008).
88. Pawlotsky, J. M. The concept of hepatitis B virus mutant escape. J. Clin. Virol. 34 (Suppl. 1), S125-S129 (2005).
89. Chen, W. N. & Oon, C. J. Hepatitis B virus mutants: An overview. J. Gastroenterol. Hepatol. 17 (Suppl.), S497-S499 (2002).
90. Hsu, H. Y. et al. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26, 786-791 (1997).
91. Carman, W. F. et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325-329 (1990).
92. Fortuin, M. et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J. Infect. Dis. 169, 1374-1376 (1994).
93. Hsu, H. Y., Chang, M. H., Ni, Y. H. & Chen, H. L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53, 1499-1503 (2004).
94. Chang, M. H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855-1859 (1997).
95. Carman, W. F. et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24, 489-493 (1996).
96. Hawkins, A. E. et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J. Hepatol. 24, 8-14 (1996).
97. Ghany, M. G. et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27, 213-222 (1998).
98. Samuel, D. et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 329, 1842-1847 (1993).
99. Gane, E. J. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132, 931-937 (2007).